![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260722_Summit_Akeso_Image-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Summit Therapeutics \/ Akeso<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Update (Phase 3, Updated Survival Analysis)<\/p>\n Modality<\/strong><\/p>\n Bispecific Antibody (PD-1 x VEGF)<\/p>\n Asset<\/strong><\/p>\n Ivonescimab<\/p>\n Target<\/strong><\/p>\n PD-1 \/ VEGF<\/p>\n Disease Area<\/strong><\/p>\n EGFR-Mutated Non-Small Cell Lung Cancer<\/p>\n Summit reported an updated overall-survival hazard ratio of 0.76 for ivonescimab plus chemotherapy in the global Phase 3 HARMONi trial, both in the full population and in Western patients. The Western subgroup improved from a hazard ratio of 0.98 at immature follow-up to 0.76 after 23.2 months, aligning with Asian results and strengthening the U.S. BLA ahead of a November 14 action date. The disclosure is directionally important but incomplete because medians, confidence intervals, event counts, and multiplicity-adjusted significance were withheld pending a medical meeting.<\/p>\n HARMONi enrolled 438 patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after a third-generation EGFR inhibitor. Patients received ivonescimab plus platinum-doublet chemotherapy or placebo plus chemotherapy. The trial had already met its progression-free-survival primary endpoint with a hazard ratio of 0.52.<\/p>\n At the April 2025 primary OS analysis, the hazard ratio was 0.79 with a 95% confidence interval of 0.62 to 1.01 and p=0.057; Western follow-up was only 9.2 months and the subgroup hazard ratio was 0.98. A September analysis produced a global hazard ratio of 0.78 and a nominal p-value of 0.0332.<\/p>\n With a June 2026 cutoff, Western median follow-up reached 23.2 months. Summit reported an OS hazard ratio of 0.76 in both the full intent-to-treat population and the 165-patient Western subgroup. The data were provided to the FDA; detailed medians, confidence intervals, and statistical analyses remain pending.<\/p>\n The updated subgroup trajectory addresses a major concern raised by the immature primary analysis: whether the China-origin molecule’s efficacy would translate to Western practice and populations. Convergence at 0.76 after longer follow-up is reassuring and is biologically plausible if early geographic divergence was driven by data maturity rather than treatment interaction.<\/p>\n The disclosure is not yet a complete statistical result. Without confidence intervals, event counts, censoring patterns, and a prespecified testing framework, the updated hazard ratio cannot be treated as definitive proof that the OS endpoint met its formal criterion.<\/p>\n Ivonescimab combines PD-1 checkpoint blockade and VEGF inhibition in a tetravalent bispecific antibody. Cooperative binding is intended to concentrate activity where both targets are abundant in the tumor microenvironment, potentially improving immune activation while reducing the systemic toxicity associated with separate anti-angiogenic therapy.<\/p>\n EGFR-mutated NSCLC has historically responded poorly to PD-1 monotherapy after targeted therapy. A benefit in this setting would support the hypothesis that simultaneous vascular and immune modulation can overcome part of that resistance.<\/p>\n The U.S. application has a November 14, 2026 goal date. Updated survival data reduce one evidentiary risk, but regulators will examine the final statistical plan, regional consistency, bleeding and vascular toxicities, chemotherapy contribution, and manufacturing comparability for global supply.<\/p>\n Ivonescimab was engineered by China-based Akeso and licensed to Summit across major ex-China territories. Successful U.S. review would be a prominent validation of China-origin late-stage innovation and of cross-border asset-development models that preserve separate regional commercialization rights.<\/p>\n The asset is being developed across first-line NSCLC and additional solid tumors, including head and neck and colorectal cancer. HARMONi is therefore both an indication-specific filing and a proof point for the broader PD-1\/VEGF bispecific class.<\/p>\n Competitors will need to show whether combining targets in one molecule improves outcomes, safety, convenience, or tumor localization versus separate checkpoint and anti-VEGF agents. Mature randomized OS and head-to-head trials will set the bar.<\/p>\n EGFR-mutated NSCLC is commonly treated first with an EGFR tyrosine kinase inhibitor such as osimertinib. After resistance develops, chemotherapy remains a central option, while conventional checkpoint inhibitors have shown limited benefit in this molecular subtype.<\/p>\n Akeso engineered ivonescimab, a tetravalent bispecific antibody that blocks PD-1 and VEGF. Summit holds rights in North and South America, Europe, the Middle East, Africa, and Japan. The molecule is approved in China and is in a broad global Phase 3 program across solid tumors.<\/p>\n This is a high-importance modality and regulatory signal. The Western hazard ratio’s improvement with mature follow-up materially strengthens the biological and commercial translation case for ivonescimab and reduces the likelihood that the early geographic difference represented a true treatment interaction.<\/p>\n The analysis must remain disciplined: a single updated hazard ratio without complete statistical context is supportive, not dispositive. The conference presentation and FDA decision will determine whether the maturation is sufficient to convert a strong PFS result and previously borderline OS analysis into an approvable package.<\/p>\n Signal strength:<\/strong> 5\/5 \u2014 High. Importance:<\/strong> High \u2014 the analysis addresses geographic generalizability, supports a near-term U.S. regulatory decision, and informs the competitive outlook for PD-1\/VEGF bispecific antibodies. Confidence:<\/strong> Medium-High \u2014 the direction and follow-up are clearly reported, but confidence is constrained until complete survival statistics and the prespecified analysis framework are disclosed.<\/p>\n","protected":false},"excerpt":{"rendered":" Summit reported an updated overall-survival hazard ratio of 0.76 for ivonescimab plus chemotherapy in the global Phase 3 HARMONi trial, both in the full population and in Western patients. The Western subgroup improved from…<\/p>\n","protected":false},"author":1,"featured_media":2108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[170,18,169],"class_list":["post-2096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-akeso","tag-non-small-cell-lung-cancer","tag-summit-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2096"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2096\/revisions"}],"predecessor-version":[{"id":2109,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2096\/revisions\/2109"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2108"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Clinical Interpretation<\/h4>\n
Mechanistic Significance<\/h4>\n
Regulatory and Cross-Border Implications<\/h4>\n
Competitive Implications<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n